Transcription Factor Differences in Cisplatin Resistant Cells

  • John S. Lazo
  • Ya-Yun Yang


Acquired resistance frequently develops in humans after the initial use of cis-diamminedichloroplatinum(II) (CP). Furthermore, both clinical and laboratory results suggest tumor cells with resistance to CP are often cross resistant to other structurally and mechanistically distinct agents. For example, the human squamous cell carcinoma SCC25/CP, which has 12-fold acquired resistance to CP, is also approximately 7-fold resistant to methotrexate, 5-fold resistant to melphalan and 3-fold resistant to cyclophosphamide (Kelley et al., 1988). Studies with other cells suggest CP resistance can be associated with cross resistance to x-radiation in human tumor cell lines (Schwartz et al., 1988). Thus, brief or repeated exposure to CP can lead to cross resistance to other cancer therapeutics but the mechanism for the drug cross-resistance is not known. Moreover, the generation of anticancer drug cross-resistance is not unique to CP and can be seen with other agents. Because many anticancer agents are genotoxic, altered gene expression might occur after drug treatment. Indeed, increased gene expression is frequently seen in cells with acquired resistance to anticancer drugs. The focus of the work described in this manuscript has been to examine the mechanistic basis for alter gene expression in a human cell line with acquired resistance to CP.


SCC26 Cell Drug Resistant Gene Human Squamous Cell Carcinoma Human Metallothionein Basal Regulatory Element 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bahnson, R.R., Becich, M., Ernstoff, M.S., Sandlow, J., Cohen, M., and Williams, R.D., 1974, Absence of immunohistochemical metallothionein staining in bladder tumors specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy, J. Urol. 152:2272–2275.Google Scholar
  2. Basu, A. and Lazo, J.S., 1991, Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum (II) resistance by v-mos, Cancer Res. 51:893–896.PubMedGoogle Scholar
  3. Compere S.J. and Palmiter R.D., 1981, DNA methylation controls the inducibility of the mouse metallothionein-I gene in lymphoid cells, Cell 25:233–240.CrossRefPubMedGoogle Scholar
  4. Cornwell, M.M. and Smith, D.E., 1993, SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity, J. Biol. Chem. 268:19505–19511.PubMedGoogle Scholar
  5. Haslinger, A. and Karin, M., 1985, Upstream promoter element of the human metallothionein-IIA gene can act like an enhancer element, Proc. Natl. Acad. Sci., USA 82:8572–8576.CrossRefPubMedGoogle Scholar
  6. Heguy, A., West, A., Richards, R.I., and Karin, M., 1986, Structure and tissue-specific expression of the human metallothionein Iβ gene, Mol. Cell Biol. 6:288149–2157.Google Scholar
  7. Kelley, S.L., Basu, A., Teicher, B.A., Hacker, M.P., Hamer, D.H. and Lazo, J.S., 1988, Overexpression of metallothionein confers resistance to anticancer drugs, Science 241:1813–1815.CrossRefPubMedGoogle Scholar
  8. Kondo, Y., Kuo, S.-M. and Lazo, J.S., 1994, Interleukin 1β mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum, J. Pharmacol. Exp. Therap. 270:1313–1318.Google Scholar
  9. Kondo, Y., Woo, E.S., Michalska, A.E., Choo, K.H.A and Lazo, J.S., In Press, Metallothionein null cells have increased sensitivity to anticancer drugs, Cancer Res.Google Scholar
  10. Lazo, J.S., Kondo, Y. Dellapiazza, D., Michalska, A.E., Choo, K.H.A., and Pitt, B.R., 1995, Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes, J. Biol. Chem. 270:5506–5510.CrossRefPubMedGoogle Scholar
  11. Lazo, J.S. and Pitt, B.R., In Press, Metallothionein and Cell Death, Ann. Rev. Pharmacol and Toxicol.Google Scholar
  12. Lee, W. Mitchell, P. and Tjian, R, 1987, Activation of transcription by two factors that bind promoter and enhancer sequence of the human metallothionein gene and SV40, Nature 325:368–372.CrossRefPubMedGoogle Scholar
  13. Lee, K.B., Parker, R.J., Bohr, V., Cornelison, T. and Reed, E., 1993, Cisplatin sensitivity/resistance to UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, Carcinogenesis 14:2177–2180.CrossRefPubMedGoogle Scholar
  14. Lemkuil, D.C., Nettesheim, D., Shaw, C.F., III and Petering, D.H., 1994, Reaction of Cd7 metallothionein with cis-diamminedichloroplatinum(II), J. Biol. Chem. 269:24792–24797.PubMedGoogle Scholar
  15. Lieberman, M.W., Beacher, L.R., and Palmiter, R.D., 1993, Ultraviolet radiation-induced metallothionein-I gene activation is associated with extensive DNA demethylation, Cell 35:207–214.CrossRefGoogle Scholar
  16. Ma, L., Weeda, G., Jochemsen, A.G., Bootsma, D., Hoeijmakers, J.H. and Eb, A.J. v.d., 1991, Molecular and functional analysis of the XPBC/ERCC promoter: transcription activity is dependent on the integrity of an Sp-1 binding site, Nucleic Acids Res. 20:217–2241.CrossRefGoogle Scholar
  17. Michalska, A. E. and Choo, K.H.A., 1993, Targeting and germ-line transmission of a null mutation at the metaUothionein I and II loci in mice, Proc. Natl. Acad. Sci. USA 90:8088–8092.CrossRefPubMedGoogle Scholar
  18. Murphy D.A., McGrown, A.T., Crowther, D., Manered, A. and Fox, B.W., 1991, MetaUothionein levels in ovarian tumors before and after chemotherapy. Br. J. Cancer 63:711–714.CrossRefPubMedGoogle Scholar
  19. Scholer, H., Haslinger, A., Heguy, A., Holtgreve, H., and Karin, M., 1986, In vivo competition between metaUothionein regulatory elements and the SV40 enhancer. Science 232:76–80.CrossRefPubMedGoogle Scholar
  20. Schwartz, J.L., Rotmensch, J., Beckett, M.A., Jaffe, D.R., ToohiU, M., Giovanazzi, S.M., McIntosh, J. and Weichselbaum, R. R, 1988, X-ray and cis-diamminedichloroplatinum(II) is cross-resistant in human tumor ceU lines, Cancer Res. 48:5133–5135.PubMedGoogle Scholar
  21. Yang, Y.-Y., Woo, E.S., Reese, C.E., Bahnson, R.R., Saijo, N. and Lazo, J.S., 1994, Human metaUothionein isoform gene expression in cisplatin-sensitive and resistant cells, Mol. Pharm. 45:453–460.Google Scholar
  22. Yang, Y.-Y., Ph.D. Dissertation, 1994, Regulation of human metaUothionein gene expression in cisplatin sensitive and resistant cells, University Microfilms, Inc.Google Scholar
  23. Yokoyama, Y., Kawamoto, T., Mitsuuchi, Y., Kurosaki, T., Toda, K., Ushiro, H., Terashima, M., Summoto, H., Kuribayashi, I., Yamamoto, Y., Maeda, T., Ikeda, H., Sagara, Y. and Shizuta, Y., 1991, Human poly(ADP-ribose) polymerase gene: cloning of the promoter region, Eur. J. Biochem. 194:521–526.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • John S. Lazo
    • 1
  • Ya-Yun Yang
    • 1
  1. 1.Department of Pharmacology and The Experimental Therapeutics Program, Pittsburgh Cancer InstituteUniversity of PittsburghPittsburghUSA

Personalised recommendations